CLINICAL TRIALS AND OBSERVATIONS Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myélome (IFM)
نویسندگان
چکیده
Murielle Roussel,1 Philippe Moreau,2 Anne Huynh,1 Jean-Yves Mary,3 Clotaire Danho,1 Denis Caillot,4 Cyrille Hulin,5 Christophe Fruchart,6 Gérald Marit,7 Brigitte Pégourié,8 Pascal Lenain,9 Carla Araujo,10 Brigitte Kolb,11 Edouard Randriamalala,12 Bruno Royer,13 Anne-Marie Stoppa,14 Mammoun Dib,15 Véronique Dorvaux,16 Laurent Garderet,17 Claire Mathiot,18 Hervé Avet-Loiseau,2 Jean-Luc Harousseau,19 and Michel Attal,1 for the Intergroupe Francophone du Myélome (IFM)
منابع مشابه
CLINICAL TRIALS AND OBSERVATIONS Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma
The Intergroupe Francophone du Myélome (IFM) initiated 2 trials in 1999 to study patients with high-risk ( 2-microglobulin level greater than 3 mg/L and chromosome 13 deletion at diagnosis) de novo multiple myeloma. In both protocols, the induction regimen consisted of vincristine, doxorubicin, and dexamethasone (VAD) followed by first autologous stem cell transplantation (ASCT) prepared by mel...
متن کاملCLINICAL TRIALS AND OBSERVATIONS High incidence of arterial thrombosis in young patients treated for multiple myeloma: results of a prospective cohort study
This prospective study evaluated the risk of arterial thrombosis in 195 consecutive patients aged 18 to 65 years with newly diagnosed multiple myeloma (MM). All patients were treated with 3 cycles of VAD (vincristine, doxorubicin, and dexamethasone) or TAD (thalidomide-AD) or PAD (bortezomib-AD) in national trials, followed by high-dose melphalan and autologous stem cell transplantation. For a ...
متن کاملCLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality
We investigated the feasibility of unrelated stem cell transplantation in 21 patients with advanced stage II/III multiple myeloma after a reduced-intensity conditioning regimen consisting of fludarabine (150 mg/m2), melphalan (100-140 mg/m2), and antithymocyte globulin (ATG; 10 mg/kg on 3 days). The median patient age was 50 years (range, 32-61 years). All patients had received at least one pri...
متن کاملRegular Article CLINICAL TRIALS AND OBSERVATIONS Trends in survival of patients with primary plasma cell leukemia: a population-based analysis
Plasma cell leukemia (PCL) is a rare and aggressive malignancy defined by the presence of more than 20% circulating plasma cells and/or an absolute plasma cell count greater than 2 3 10/L in a peripheral blood smear. It accounts for approximately 1% to 2% of all plasma cell dyscrasias and presents in 2 forms, primary and secondary PCL. Primary PCL (pPCL) represents approximately 60% of PCL case...
متن کاملCLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Superiority of thalidomide and dexamethasone over vincristine-doxorubicin- dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma
The aim of the present study was to compare thalidomide-dexamethasone (Thal-Dex) and vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous peripheral blood stem-cell (PBSC) transplantation for multiple myeloma (MM). For this purpose, we performed a retrospective matched case-control analysis of 200 patients who entered 2 consecutive studies from 1996 to 200...
متن کامل